Crohn's disease: Remicade prescription to decrease, while Humira's increases

Published on April 8, 2010 at 8:30 AM · No Comments

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed gastroenterologists estimate that (assuming no new data on adverse events emerge) they will treat fewer Crohn's disease patients with Centocor Ortho Biotech/Merck/Mitsubishi Tanabe's Remicade by the end of 2010, while the percentage of biologics-treated patients receiving Abbott/Eisai's Humira will increase to 36 percent. Surveyed gastroenterologists also indicate that the percentage of patients treated with a biologic who receive UCB/Otsuka's Cimzia will rise from 9 percent to 12 percent within the next year.

The new Physician & Payer Forum report entitled The Expanding Biologics Landscape in CD and UC: Clinician and Payer Perspective on the Role of Premium-Priced Biologics in CD and UC Treatment also finds that, on average, surveyed gastroenterologists report prescribing Remicade to 31 percent of their ulcerative colitis patients. Fifty-three percent of surveyed gastroenterologists prescribe Remicade to between 1 percent and 20 percent of their ulcerative colitis patients, while 13 percent of surveyed gastroenterologists prescribe Remicade to between 91 percent and 100 percent of patients.

Additionally, the report finds that 8 percent of gastroenterologists report that they are not currently treating any of their ulcerative colitis patients with Remicade.

"Gastroenterologists' reservation of Remicade for later-line use reflects the effectiveness of nonbiological therapies for ulcerative colitis such as aminosalicylates and corticosteroids as well as the fact that Remicade became available somewhat recently as the only approved biologic for ulcerative colitis," said Decision Resources Analyst Kathryn Benton.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post